

**APPLICANT** (stamp or sticker acceptable)      **PATIENT NHI:** .....      **REFERRER** Reg No: .....

Reg No: .....      First Names: .....      First Names: .....

Name: .....      Surname: .....      Surname: .....

Address: .....      DOB: .....      Address: .....

.....      Address: .....      .....

.....      .....

Fax Number: .....      Fax Number: .....

**Methylphenidate Hydrochloride Extended Release** (Concerta; Ritalin LA)

**Initial application — ADHD**

Applications only from a paediatrician, psychiatrist, medical practitioner on the recommendation of a paediatrician or psychiatrist (in writing) or nurse practitioner on the recommendation of a paediatrician or psychiatrist (in writing). Approvals valid without further renewal unless notified.

**Prerequisites**(tick boxes where appropriate)

<input type="checkbox"/> ADHD (Attention Deficit and Hyperactivity Disorder)
<b>and</b> <input type="checkbox"/> Diagnosed according to DSM-IV or ICD 10 criteria
<b>and</b>
<input type="checkbox"/> Applicant is a paediatrician or psychiatrist
<b>or</b> <input type="checkbox"/> Applicant is a medical practitioner or nurse practitioner and confirms that a paediatrician or psychiatrist has been consulted within the last 2 years and has recommended treatment for the patient in writing
<b>and</b>
<input type="checkbox"/> Patient is taking a currently subsidised formulation of methylphenidate hydrochloride (immediate-release or sustained-release) which has not been effective due to significant administration and/or difficulties with adherence
<b>or</b> <input type="checkbox"/> There is significant concern regarding the risk of diversion or abuse of immediate-release methylphenidate hydrochloride
<b>or</b>
<input type="checkbox"/> Patient meets the Special Authority criteria for SA2411 methylphenidate hydrochloride
<b>and</b> <input type="checkbox"/> Patient is unable to access other methylphenidate hydrochloride presentations under Special Authority criteria SA2411 due to an out of stock (see note)

Note: Criterion 2 is to permit short-term funding to cover an out-of-stock on tab extended-release Methylphenidate ER – Teva and tab sustained-release 20 mg Rubifen SR subsidised under SA2411 (<https://schedule.pharmac.govt.nz/2025/02/01/SA2411.pdf>).

**Initial application — Narcolepsy\***

Applications only from a neurologist or respiratory specialist. Approvals valid without further renewal unless notified.

**Prerequisites**(tick box where appropriate)

The patient suffers from narcolepsy

Note: \*narcolepsy is not a registered indication for Concerta or Ritalin LA.

I confirm the above details are correct and that in signing this form I understand I may be audited.

Signed: ..... Date: .....

Post application to Ministry of Health, Private Bag 3015, Wanganui – email: [customerservice@health.govt.nz](mailto:customerservice@health.govt.nz)